Lorazepam or diazepam for convulsive status epilepticus: A meta-analysis

Area of Science:

• Neurology
• Pharmacology
• Clinical Trials

Background:

• Convulsive status epilepticus (CSE) is a critical neurological condition requiring prompt treatment.
• The optimal benzodiazepine for CSE management remains debated, impacting clinical practice.
• Lorazepam and diazepam are commonly used first-line agents for CSE.

Purpose of the Study:

• To conduct a meta-analysis comparing the efficacy and safety of lorazepam versus diazepam in treating CSE.
• To determine if one benzodiazepine offers superior outcomes in CSE patients of different age groups.

Main Methods:

• Systematic literature search of major databases (PubMed, Medline, Embase, Cochrane, Google Scholar) from 1966 to February 2014.
• Inclusion of six studies with 970 patients (574 children, 396 adults), assessing trial quality using Jadad scale and CONSORT checklist.
• Data analysis using fixed-effects or random-effects models for continuous and dichotomous outcomes.

Main Results:

• Meta-analysis revealed no statistically significant differences between lorazepam and diazepam regarding seizure control.
• Adverse effect profiles were comparable between the two treatment groups across all age demographics.
• Efficacy and safety outcomes were consistent for both pediatric and adult CSE patients.

Conclusions:

• Lorazepam and diazepam demonstrate equivalent efficacy and safety profiles for the first-line treatment of CSE in both children and adults.
• Either agent can be considered a reasonable choice for initial CSE therapy.
• Further high-quality randomized controlled trials are warranted to solidify these findings.